Nurix Therapeutics, Inc. Common stock
Symbol: NRIX (NASDAQ)
0.00
▼ (-100.00%) -9.200
Company Description:
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $9.2
- Yesterday High: $9.25
- Yesterday Low: $8.94
- Yesterday Volume: 670.87K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Nurix Therapeutics, Inc. Common stock
- Website: http://www.nurixtx.com
- Listed Date: 2020-07-24
- Location: SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001549595
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $684.22M
- Round Lot: 100
- Outstanding Shares: 76.45M
- Asset Type: CS
RECENT FILINGS FOR NRIX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-03 | 8-K | View |
| 2025-08-22 | 8-K | View |
| 2025-08-01 | 4 | View |
| 2025-08-01 | 144 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-09 | 10-Q | View |
| 2025-07-09 | 8-K | View |
| 2025-06-12 | 8-K | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
Latest News on NRIX